The potential of ribonucleotide reductase M2 as a novel prognostic maker and therapeutic target to inhibit medulloblastoma proliferation, migration, and invasiveness

Abstract

The crucial role of ribonucleotide reductase M2 (RRM2) enzyme in cancer occurrence and progression has been well-established, but its specific function and significance in medulloblastoma (MB) remains largely unknown. First, we conducted a bioinformatics analysis of public genomic databases and observed highly expressed RRM2 in MB and an association of high RRM2 expression with adverse outcomes. In addition, by collecting clinical MB specimens for polymerase chain reaction (PCR), western blotting (WB), and immunohistochemistry (IHC), RRM2 was confirmed to be highly expressed in tumor tissues. Furthermore, immunohistochemical analysis linked adverse prognosis to high RRM2 expression. Moreover, knocking down RRM2 significantly inhibited MB cell proliferation, migration, and invasion in vitro. This report is the first to demonstrate the oncogenic role of RRM2 in MB, associated with adverse patient outcomes. Knocking down RRM2 contributes to weakened proliferating, migrating, and invading potentials of MB cells. RRM2 is expected to be a novel prognostic biomarker and therapeutic target for MB.

Keywords

invasiveness / medulloblastoma / migration / proliferation / RRM2

References

[1] HovestadtV, SmithKS, BihannicL, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019;572(7767):74-79.

[2] GrammelD, Warmuth-Metz M, von BuerenAO, et al. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol. 2012;123(4):601-614.

[3] TaylorMD, Northcott PA, KorshunovA, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-472.

[4] GajjarAJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol. 2014;11(12):714-722.

[5] SethiRV, Giantsoudi D, RaifordM, et al. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int J Radiat Oncol Biol Phys. 2014;88(3):655-663.

[6] LouisDN, PerryA, WesselingP, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231-1251.

[7] MorikawaT, HinoR, UozakiH, et al. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 2010;41(12):1742-1748.

[8] LiC, ZhengJ, ChenS, et al. RRM2 promotes the progression of human glioblastoma. J Cell Physiol. 2018;233(10):6759-6767.

[9] SunH, YangB, ZhangH, et al. RRM2 is a potential prognostic biomarker with functional significance in glioma. Int J Biol Sci. 2019;15(3):533-543.

[10] Corrales-GuerreroS, Cui T, Castro-AceitunoV, et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 2023;570:216308.

[11] YangY, LinJ, GuoS, et al. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell Int. 2020;20(1):587.

[12] Abdel-RahmanMA, Mahfouz M, HabashyHO. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance. Diagn Pathol. 2022;17(1):1.

[13] JiangX, LiY, ZhangN, et al. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. Cell Biosci. 2021;11(1):74.

[14] NunesC, Depestel L, MusL, et al. RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Sci Adv. 2022;8(28):eabn1382.

[15] BarrettT, Wilhite SE, LedouxP, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(Database issue):D991-D995.

[16] SmollNR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541-1544.

[17] YoshidaY, Tsunoda T, DoiK, et al. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res. 2011;31(7):2535-2539.

[18] RahmanMA, AminARMR, WangD, et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013;19(13):3416-3428.

[19] XiaG, WangH, SongZ, Meng Q, MengQ, HuangX, HuangX. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res. 2017;36(1):107.

[20] MorikawaT, MaedaD, KumeH, Homma Y, FukayamaM. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 2010;57(6):885-892.

[21] WangL, MengL, WangXW, Ma GY, ChenJH. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014;35(3):1899-1906.

[22] SuYF, WuTF, KoJL, et al. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One. 2014;9(3):e91644.

[23] WangZ, LiuX, HoRL, HoRLKY, LamCWK, Chow MSS. Precision or personalized medicine for cancer chemotherapy: is there a role for herbal medicine. Molecules. 2016;21(7):889.

[24] XiongW, ZhangB, YuH, ZhuL, YiL, JinX. RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway. Adv Sci (Weinh). 2021;8(18):e2100881.

[25] GuoY, HuangP, NingW, Zhang H, YuC. Identification of core genes and pathways in medulloblastoma by integrated bioinformatics analysis. J Mol Neurosci. 2020;70(11):1702-1712.

[26] ZhangM, WangJ, YaoR, WangL. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer. Int J Gynecol Cancer. 2013;23(4):659-666.

[27] ZhongZ, CaoY, YangS, Zhang S. Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway. Pharmazie. 2016;71(5):280-284.

[28] ZhangH, LiuX, WardenCD, et al. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer. 2014;14:664.

[29] RahmanMA, AminARMR, WangX, et al. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Contr Release. 2012;159(3):384-392.

RIGHTS & PERMISSIONS

2024 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.